Preview

Obstetrics, Gynecology and Reproduction

Advanced search

JAK2V617F-positive clonal hematopoiesis of indeterminate potential in pregnant women

https://doi.org/10.17749/2313-7347.2019.13.3.204-210

Full Text:

Abstract

Aim: to assess the prevalence of V617F somatic mutation of the JAK2 gene in pregnant women.

Materials and methods. This non-interventional study was performed in the framework of routine clinical practice and included 1532 samples of venous blood from pregnant women who applied for medical assistance at Krasnoyarsk Regional Clinical Center for Maternal and Child Welfare. We used blood samples left after all routine laboratory tests had been done. These leftovers were pooled in the way that ensured an equal ratio of nucleated cells. Each pool contained 7 separate blood samples. The unused samples that remained after the pooling were frozen and stored at –20°C until the end of entire testing procedure. The V617F JAK2 mutation was detected by the real-time allele-specific polymerase chain reaction test.

Results. Among the examined pregnant women, 6 (0.4 %) were identified as carriers of V617F JAK2 mutation. Three women with this mutation suffered from infertility for 4, 5, and 10 years; two of them had repeated miscarriages in the first trimester of pregnancy. The 6 women – carriers of this mutations had no concomitant genetic polymorphisms typical of thrombophilia (factors FII, FV), and no abnormal coagulation characteristics. Analysis of their medical records showed that in the past, two of these women had gestational hypertension, one developed a clinical picture of preeclampsia, and another one (with the maximum presence of the mutant allele) had a history of acute lymphoblastic leukemia followed by stable remission.

Conclusion. The routine laboratory detection of the V617F JAK2 mutation can facilitate timely identification of the increased risk of pregnancy pathology, as well as timely diagnosis of hematological cancer.

About the Authors

I. A. Olkhovskiy
Krasnoyarsk branch of National Research Center for Hematology, Health Ministry of Russian Federation; Federal Research Center «Krasnoyarsk Scientific Center, Siberian Branch of Russian Academy of Sciences»
Russian Federation

Igor A. Olkhovskiy – MD, PhD, Director of the Krasnoyarsk branch of National Research Center for Hematology, Health Ministry of Russian Federation

50/45 Akademgorodok, Krasnoyarsk 660036; 50 Akademgorodok, Krasnoyarsk 660036



J. G. Garber
Krasnoyarsk Regional Clinical Center for Maternal and Child Welfare
Russian Federation

Julia G. Garber – Deputy Head of the Department of Obstetrics and Gynecology

2а Academician Kirenskogo St., Krasnoyarsk 660074



A. S. Gorbenko
Krasnoyarsk branch of National Research Center for Hematology, Health Ministry of Russian Federation
Russian Federation

Aleksey S. Gorbenko – Researcher

50/45 Akademgorodok, Krasnoyarsk 660036



M. A. Stolyar
Krasnoyarsk branch of National Research Center for Hematology, Health Ministry of Russian Federation; Federal Research Center «Krasnoyarsk Scientific Center, Siberian Branch of Russian Academy of Sciences»
Russian Federation

Marina A. Stolyar – Researcher

50/45 Akademgorodok, Krasnoyarsk 660036; 50 Akademgorodok, Krasnoyarsk 660036



O. M. Miller
Krasnoyarsk Regional Clinical Center for Maternal and Child Welfare
Russian Federation

Olga M. Miller – Researcher

2а Academician Kirenskogo St., Krasnoyarsk 660074



E. S. Kostina
Krasnoyarsk Regional Clinical Center for Maternal and Child Welfare
Russian Federation

Ekaterina S. Kostina – Researcher

2а Academician Kirenskogo St., Krasnoyarsk 660074



Yu. Yu. Komarovskiy
Krasnoyarsk branch of National Research Center for Hematology, Health Ministry of Russian Federation
Russian Federation

Yuriy Yu. Komarovskiy – Researcher

50/45 Akademgorodok, Krasnoyarsk 660036



V. V. Potilitsina
Krasnoyarsk Regional Clinical Center for Maternal and Child Welfare
Russian Federation

Victoria V. Potilitsina – Clinical Laboratory Specialist

2а Academician Kirenskogo St., Krasnoyarsk 660074



References

1. Silver A., Jaiswal S. Clonal hematopoiesis: Pre-cancer PLUS. Adv Cancer Res. 2019;141:85–128. DOI: 10.1016/bs.acr.2018.12.003.

2. Libby P., Ebert B. CHIP (Clonal Hematopoiesis of Indeterminate Potential). Circulation. 2018;138(7):666–8. DOI: 10.1161/circulationaha.118.034392.

3. Patterson-Fortin J., Moliterno A. Molecular pathogenesis of myeloproliferative neoplasms: influence of age and gender. Curr Hematol Malig Rep. 2017;12(5):424–31. DOI: 10.1007/s11899-017-0411-0.

4. Smith B., Savona M., Komrokji R. Challenges in myelodysplastic/ myeloproliferative neoplasms (MDS/MPN). Clin Lymphoma Myeloma Leuk. 2019;19(1):1–8. DOI: 10.1016/j.clml.2018.11.019.

5. Skeith L., Carrier M., Robinson S. et al. Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. Blood. 2017;129(8):934–9. DOI: 10.1182/blood-2016-09-728006.

6. Shmakov R.G., Polushkina E.S., Akhmedova A.I. et al. Principles of pregnancy management in women with Ph-negative myeloproliferative neoplasms. [Principy vedeniya beremennosti u zhenshchin s Ph-negativnymi mieloproliferativnymi novoobrazovaniyami]. Akusherstvo i ginekologiya. 2017;12:46–51. (In Russ.). DOI: 10.18565/aig.2017.12.46-51.

7. Melikyan A.L., Turkina A.G., Kovrigina A.M. et al. Clinical recommendations for diagnosis and therapy of Ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis). [Klinicheskie rekomendacii po diagnostike i terapii Ph-negativnyh mieloproliferativnyh zabolevanij (istinnaya policitemiya, essencial'naya trombocitemiya, pervichnyj mielofibroz)]. Gematologiya i transfuziologiya. 2017;62(pril. 1):1–60. (In Russ.). DOI: 10.18821/0234-5730-2017-62-1-S1-1-60.

8. Robinson S.E., Harrison C.N. The management and outcome of pregnancy in patients with myeloproliferative neoplasms. In: Disorders of thrombosis and hemostasis in pregnancy. A guide to management. Eds. H. Cohen, P. O'Brien. London: Springer, 2012. 185-195.

9. Lavi N., Horowitz N., Brenner B. An update on the management of hematologic malignancies in pregnancy. Womens Health (Lond). 2014;10(3):255–66. DOI: 10.2217/whe.14.17.

10. Jaiswal S., Natarajan P., Silver A. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–21. DOI: 10.1056/nejmoa1701719.

11. Tuchayi A., Sheth S., Smith R. The evaluation of cardiac disorders and systemic hypertension in JAK2V617F positive patients at a multicenter institution. J Hematol Thromb. 2016;2(1):4. DOI: 10.13188/2380-6842.1000014.

12. Passamonti S., Biguzzi E., Cazzola M. et al. The JAK2 V617F mutation in patients with cerebral venous thrombosis. J Thromb Haemost. 2012;10(6):998–1003. DOI: 10.1111/j.1538-7836.2012.04719.x.

13. Mironov K.O., Dunaeva E.A., Dribnokhodova O.P. et al. Frequency of V617F mutation detection in JAK2 gene in persons after ischemic stroke. [Chastota obnaruzheniya mutacii V617F v gene JAK2 u lic, perenesshih ishemicheskij insul't]. IX Vserossijskaya nauchno-prakticheskaya konferenciya s mezhdunarodnym uchastiem «Molekulyarnaya diagnostika 2017»: sbornik trudov. Moskva, 2017. 75–6. (In Russ.).

14. Smalberg J., Arends L., Valla D. et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120(25):4921–8. DOI: 10.1182/blood-2011-09-376517.

15. Olkhovskiy I.A., Karapetyan G.E., Gorbenko A.S. et al. The identifiability of patients with carcinogenic somatic mutation of Junus kinase-2 (V617F JAK2) within the framework of programs of dispensary and preventive examinations. [Vyyavlyaemost' pacientov s onkogennoj somaticheskoj mutaciej yanuskinazy-2 (V617F JAK2) v ramkah programm dispansernogo i profilakticheskogo osmotrov]. Klinicheskaya laboratornaya diagnostika. 2016;61(5):275–8. (In Russ.). DOI: 10.18821/0869-2084-2016-61-5-275-278.

16. Gorbenko A.S., Stolyar M.A., Subbotina T.N. et al. Developing method for allelic somatic mutations burden of Janus kinase 2 (V617F JAK2) detection in pools of venous blood samples. [Razrabotka metoda opredeleniya allel'noj nagruzki somaticheskoj mutacii V617F v gene JAK2 (yanus-kinazy-2) v pulah prob venoznoj krovi]. Laboratornaya sluzhba. 2016;5(1):19–25. (In Russ.). DOI: 10.17116/labs20165119-25.

17. Horowitz N.A., Lavi N., Nadir Y., Brenner B. Haematological malignancies in pregnancy: An overview with an emphasis on thrombotic risks. Thromb Haemost. 2016;116(4):613–7. DOI: 10.1160/TH16-02-0099.

18. Nemer W., Grandis M., Brusson M. Abnormal adhesion of red blood cells in polycythemia vera: a prothrombotic effect? Thromb Res. 2014;133(Suppl 2):S107–S111. DOI: 10.1016/s0049-3848(14)50018-7.

19. Coucelo M., Caetano G., Sevivas T. et al. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. Int J Hematol. 2014;99(1):32–40. DOI: 10.1007/s12185-013-1475-9.

20. Olkhovskiy I.A., Stolyar M.A. Features of platelet aggregation in patients with JAK2 gene mutation: gender differences and aspirin effect. [Osobennosti agregacionnoj aktivnosti trombocitov u pacientov s mutaciej v gene JAK2: gendernye otlichiya i effekt acetilsalicilovoj kisloty]. Gematologiya i transfuziologiya. 2014;59(1):11–4. (In Russ.).

21. Grandone E., Colaizzo D., Tiscia G. et al. Impact of common thrombophilias and JAK2 V617F on pregnancy outcomes in unselected Italian women. J Thromb Haemost. 2011;9(3):496–501. DOI: 10.1111/j.1538-7836.2011.04183.x.

22. Nielsen C., Bojesen S., Nordestgaard B. et al. JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica. 2014;99(9):1448–55. DOI: 10.3324/haematol.2014.107631.


For citation:


Olkhovskiy I.A., Garber J.G., Gorbenko A.S., Stolyar M.A., Miller O.M., Kostina E.S., Komarovskiy Y.Y., Potilitsina V.V. JAK2V617F-positive clonal hematopoiesis of indeterminate potential in pregnant women. Obstetrics, Gynecology and Reproduction. 2019;13(3):204-210. (In Russ.) https://doi.org/10.17749/2313-7347.2019.13.3.204-210

Views: 44


ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)